Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Cancer Medicine ( IF 2.9 ) Pub Date : 2020-04-05 , DOI: 10.1002/cam4.3013
Mary Ellen Urick ₁ , Daphne W Bell ₁

Affiliation

Despite advancements over the past decade revealing molecular aberrations characteristic of endometrial cancer (EC) subtypes, serous ECs remain difficult to treat and associated with poor outcomes. This is due, in part, to the rarity of these tumors within clinical trials and the inability to directly target the most frequent genomic abnormalities. One of the most commonly somatically mutated genes in serous ECs is the tumor suppressor F‐box and WD repeat domain containing 7 (FBXW7 ).

中文翻译：

FBXW7 突变浆液性子宫内膜癌细胞的蛋白质组学分析揭示了 PADI2 的上调，PADI2 是一个潜在的治疗靶点。

尽管过去十年的进展揭示了子宫内膜癌 (EC) 亚型的分子畸变特征，但浆液性 EC 仍然难以治疗且与不良预后相关。部分原因是这些肿瘤在临床试验中很少见，并且无法直接针对最常见的基因组异常。浆液性 EC 中最常见的体细胞突变基因之一是肿瘤抑制因子F-box 和包含 7 ( FBXW7 ) 的 WD 重复结构域。

更新日期：2020-04-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11